Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/ajp.138.6.838 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional pathology of neuroleptic-induced dystonia based on the striatal striosome-matrix dopamine system in humans.
J Neurol Neurosurg Psychiatry
January 2025
Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan
Neuroleptic-induced dystonia is a source of great concern in clinical practice because of its iatrogenic nature which can potentially lead to life-threatening conditions. Since all neuroleptics (antipsychotics) share the ability to block the dopamine D-type receptors (DRs) that are highly enriched in the striatum, this drug-induced dystonia is thought to be caused by decreased striatal DR activity. However, how associations of striatal DR inactivation with dystonia are formed remains elusive.
View Article and Find Full Text PDFValidation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.
Mov Disord
December 2024
San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
Background: Electronic medical record (EMR)-based studies hold great potential for epidemiologic investigations of Parkinson's disease (PD) causal factors and phenomenology, but diagnostic misclassification may obscure or bias inferences.
Objectives: The aims were to determine the validity of PD diagnostic codes in the Veterans Administration (VA) national electronic medical databases and develop recommendations for maximizing ascertainment accuracy.
Methods: We investigated a cohort of 146,776 veterans who utilized VA healthcare between 1999 and 2021.
Prospective Five-Year Follow-Up of Patients with Schizophrenia Suspected with Parkinson's Disease.
Parkinsons Dis
May 2022
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Objective: It is difficult to distinguish patients with schizophrenia with neuroleptic-induced parkinsonism (NIP) from those with existing idiopathic Parkinson's disease when their striatal dopamine transporter uptake is reduced. There is a possibility of misdiagnosis of Parkinson's disease in patients with schizophrenia as schizophrenia with NIP, which leads to inappropriate treatment. This prospective study aimed at determining the underlying pathophysiology using detailed clinical and psychological assessments.
View Article and Find Full Text PDFAntiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Ann Pharm Fr
November 2022
Department of Pharmacology, Vignan Institute of Pharmaceutical Sciences, Deshmukhi, Yadadri, Bhongiri, 508284, Telangana, India.
Objectives: Improving economy and well-being in developing nations like India has expanded life expectancy and changed the attention from transmittable to non transmittable diseases such as Parkinson's disease. Tabebuia impetiginosa has been utilized by cultivators as a general tonic, immunostimulant, adaptogen and also in motor disorders. The present investigation was to explore the antiparkinsonian activity of Tabebuia impetiginosa bark by experimental methods.
View Article and Find Full Text PDFEfficacy of low-dose D/D partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study.
Neuropsychiatr Dis Treat
August 2019
Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University of Medicine, Shanghai, People's Republic of China.
Objective: Some lines of evidence show that D/D receptor partial agonist pramipexole may be effective in the treatment of extrapyramidal symptoms (EPS) and psychiatric symptoms of schizophrenia. Therefore, we analyzed whether a low dose of pramipexole (0.375-0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!